An interventional study of Personalised dietary intervention and Standard dietary counselling in Type 2 Diabetes, Nutrition and Carbohydrate, sponsored by Steno Diabetes Center Copenhagen. Not yet recruiting at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Steno Diabetes Center Copenhagen · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen — 9 open to participants now, 10 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Steno Diabetes Center Copenhagen.
Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, this one is the 6th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2027, is one of 17 with no phase, and was the 31st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →9 of the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18–74
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18–75
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 65+
By country, each count listing its studies:
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 94 across the 24 interventional studies, 148 across the 6 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 23 are open to participants now.
3 of the studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07262788Steno Diabetes Center CopenhagenA Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes | 2027-03 |
| NCT07645079Steno Diabetes Center CopenhagenAutomated Insulin Delivery Versus Daily Injections for Hospital Diabetes Care | 2027-07-15 |
| NCT07641309Steno Diabetes Center CopenhagenMeasurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with type 2 diabetes receive standard dietary advice to improve glycaemic control. However, blood glucose responses to the same foods can vary considerably between individuals. This randomised controlled trial aims to investigate whether personalised carbohydrate recommendations guided by continuous glucose monitoring (CGM) improve glycaemic control (HbA1c) compared with standard dietary care.
A total of 130 adults with type 2 diabetes will be randomly assigned to one of two groups. The study will include a 6-month intervention period followed by a 6-month follow-up period. The intervention group will receive dietitian-led personalised carbohydrate recommendations informed by CGM data, supplemented by group-based education in carbohydrate counting. The control group will receive standard individual dietary counselling provided by a dietitian without the use of CGM.
The primary outcome is the between-group difference in change in HbA1c from baseline to 6 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CGM-supported personalised carbohydrate recommendations
Behavioral: Personalised dietary intervention
Standard dietary counselling for type 2 diabetes
Behavioral: Standard dietary counselling
Participants will receive structured, personalised dietary recommendations supported by continuous glucose monitoring (CGM). Initial carbohydrate recommendations will be based on approximately 35% of total energy intake and translated into individual targets expressed as grams of carbohydrate per day and per meal. These targets will be adjusted throughout the intervention based on individual needs and glycaemic responses rather than prescribed as fixed amounts. CGM data will be used to assess individual postprandial glucose responses and guide adjustments to carbohydrate intake and its distribution throughout the day. The intervention will also include education in basic carbohydrate counting and dietitian-led counselling to support the implementation and maintenance of dietary changes.
Participants will receive standard dietary counselling for type 2 diabetes based on current dietary recommendations, without CGM-guided personalisation of carbohydrate intake. The counselling will include one initial 60-minute individual consultation with a dietitian, followed by two 30-minute follow-up consultations.
Change in HbA1c
Between-group difference in change in HbA1c (mmol/mol) from baseline to 6 months
Time frame: Baseline to 6 months
Change in HbA1c at 12 months
Between-group difference in HbA1c change (mmol/mol)
Time frame: Baseline to 12 weeks and 12 months
Time in range (TIR)
Percentage of CGM time with glucose 3.9-10.0 mmol/L
Time frame: Baseline, 6 and 12 months
Time above range (TAR)
Percentage of CGM time with glucose \>10.0 mmol/L
Time frame: Baseline, 6 and 12 months
Time below range (TBR)
Percentage of CGM time with glucose \<3.9 mmol/L
Time frame: Baseline, 6 and 12 months
Estimated HbA1c
HbA1c estimated from CGM data (mmol/mol)
Time frame: Baseline, 6 and 12 months
Change in glycaemic variability
Coefficient of variation (%) derived from CGM
Time frame: Baseline, 6 and 12 months
Body mass index (BMI)
kg/m²
Time frame: Baseline, 6 and 12 months
Waist and hip circumference
cm
Time frame: Baseline, 6 and 12 months
Blood pressure
Systolic and diastolic (mmHg)
Time frame: Baseline, 6 and 12 months
plasma glucose
mmol/L
Time frame: Baseline, 6 and 12 months
Plasma insulin
pmol/L
Time frame: Baseline, 6 and 12 months
C-peptide
pmol/L
Time frame: Baseline, 6 and 12 months
Total cholesterol
mmol/L
Time frame: Baseline, 6 and 12 months
LDL cholesterol
mmol/L
Time frame: Baseline, 6 and 12 months
HDL cholesterol
mmol/L
Time frame: Baseline, 6 and 12 months
Triglycerides
mmol/L
Time frame: Baseline, 6 and 12 months
Diabetes distress (questionnaire)
Problem Areas in Diabetes (PAID) score
Time frame: Baseline, 6 and 12 months
Treatment satisfaction (questionnaire)
Diabetes Treatment Satisfaction Questionnaire (DTSQ) score
Time frame: Baseline, 6 and 12 months
Change in glucose-lowering medication
Changes in type and dose of glucose-lowering medication
Time frame: Baseline, 6 and 12 months
Personality traits (questionnaire)
Big Five Inventory (BFI-44) scores
Time frame: Baseline
Dietary intake
Total energy intake and macronutrient composition from a 3-day food record
Time frame: Baseline and 6 months
Physical activity
Physical activity level measured with an AX3 accelerometer worn for 7 days
Time frame: Baseline and 6 months
Carbohydrate estimation ability (questionnaire)
Accuracy of participants' carbohydrate estimates
Time frame: Baseline, 6 and 12 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Sep 2028, 19 months later.
Of 2,068 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 19 months is close to that.
Counting every sponsor, half of 2,245 studies reached it within 21 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Steno Diabetes Center Copenhagen →